Annals of Oncology Advance Access published online on February 28, 2006
Annals of Oncology, doi:10.1093/annonc/mdl031
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Medical Oncology, University Campus Bio-Medico, Rome, Italy
* To whom correspondence should be addressed. Introduction: Angiogenesis has been correlated with increased invasion and metastases in a variety of human neoplasms. Inadequate inhibition of the growth of tumor microvessels by anticancer agents may result in treatment failure, rated clinically as progressive or stable disease. We designed this trial to investigate the modification of the vascular endothelial growth factor (VEGF) and interferon- Materials and methods: Forty-five metastatic colorectal cancer patients were prospectively evaluated for circulating levels of VEGF and IFN- Results: Basal serum VEGF median levels were significantly decreased just at the first day (after the first treatment infusion (P = 0.016). The VEGF persisted at the following time points reaching the highest statistical significance 92 days after the first infusion (P < 0.0001). On the contrary, IFN- Conclusions: This study suggests that a cetuximab may induce a modulation of VEGF circulating levels. The reduction of VEGF serum levels is a sudden and long lasting phenomenon. Moreover, in our study we identified a IFN-
Received November 22, 2005
Revised January 23, 2006
Accepted January 26, 2006
original article
Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients
B. Vincenzi 1,
D. Santini 1,
A. Russo 2 *,
M. Silletta 1,
M. Gavasci 3,
F. Battistoni 3,
G. Di Cuonzo 3,
L. Rocci 1,
N. Gebbia 2,
and
G. Tonini 1
2 Department of Oncology, Università di Palermo, Italy
3 Laboratory Medicine, University Campus Bio-Medico, Rome, Italy
A. Russo, E-mail: lab-oncobiologia{at}usa.net
Abstract 
(IFN-) in advanced colorectal cancer patients during treatment with a weekly combination of cetuximab plus irinotecan. during the treatment with cetuximab (initial dose of 400 mg/m2, followed by weekly infusions of 250 mg/m2) plus weekly irinotecan (90 mg/m2). The circulating levels of the cytokines were assessed at the following time points: just before and at 1, 21, 50 and 92 days after the start of cetuximab plus irinotecan treatment. values showed a statistical significant increase one day after the first infusion (P < 0.0001). This effect persisted 21 days after the treatment start (P = 0.001), but was no more evident at the following time points. Moreover, a linear regression model with variance analysis showed a significant negative correlation between VEGF and IFN- values 1, 21 and 50 days after the treatment beginning (P = 0.002, 0.001 and 0.047, respectively). increase, even if the specific role of this behavior remains to be investigated.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Siena, A. Sartore-Bianchi, F. Di Nicolantonio, J. Balfour, and A. Bardelli Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer J Natl Cancer Inst, October 7, 2009; 101(19): 1308 - 1324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Vincenzi, D. Santini, S. Galluzzo, A. Russo, F. Fulfaro, M. Silletta, F. Battistoni, L. Rocci, B. B. Zobel, V. Adamo, et al. Early Magnesium Reduction in Advanced Colorectal Cancer Patients Treated with Cetuximab Plus Irinotecan as Predictive Factor of Efficacy and Outcome Clin. Cancer Res., July 1, 2008; 14(13): 4219 - 4224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Dome, M. J.C. Hendrix, S. Paku, J. Tovari, and J. Timar Alternative Vascularization Mechanisms in Cancer: Pathology and Therapeutic Implications Am. J. Pathol., January 1, 2007; 170(1): 1 - 15. [Abstract] [Full Text] [PDF]
|
|